New drug combo aims to shrink pancreatic tumors before surgery

NCT ID NCT05209074

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination for up to 90 days, then undergo surgery. The main goal is to find a safe dose and see how well the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ivosidenib (a drug targeting a specific gene mutation) combined with chemotherapy (mFOLFIRINOX)
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for a subset of pancreatic cancer patients with an IDH1 mutation.
What could go wrong
This is a very early, small Phase 1 trial with only 16 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOSQUAMOUS CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.